First participant dosed with acoramidis in act-early, the first ever attr primary prevention study

- attribute-cm, bridgebio's phase 3 clinical trial of acoramidis in patients with attr-cm, achieved statistical significance in reducing the risk of acm or first cvh versus placebo in attrv-cm patients (59.1% risk reduction) , establishing the mechanistic hypothesis that stabilizing ttr may delay or prevent attrv-cm
ACT Ratings Summary
ACT Quant Ranking